Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2017-01-05 Board/Management Inform…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Armin Reininger joins Sobi as Senior Vice President, Head of Global Medical and Scientific Affairs
Board/Management Information Classification · 98% confidence The document is a press release announcing a specific personnel change: the appointment of Armin Reininger as Senior Vice President, Head of Global Medical and Scientific Affairs. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The document is short and focuses entirely on this personnel news, not on financial results (ER/IR) or regulatory filings (RPA/RNS).
2017-01-05 English
Armin Reininger blir Senior Vice President, Head of Global Medical and Scientific Affairs
Board/Management Information Classification · 98% confidence The document is a press release dated January 5, 2017, announcing the appointment of Armin Reininger as Senior Vice President, Head of Global Medical and Scientific Affairs at Swedish Orphan Biovitrum AB (Sobi). This announcement details a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3085 chars), but its content is a direct announcement of a management change, not an announcement about the publication of a separate report, making MANG the most appropriate classification.
2017-01-05 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JUL-SEP 2016' (Interim Report July-September 2016). It contains comprehensive financial statements, including income statements, cash flow analysis, product revenue breakdowns, and management commentary for the third quarter of 2016. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2016
2016-10-27 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Q3 Report' for 2016, which contains comprehensive financial statements, business highlights, management commentary, and detailed financial tables (e.g., revenue by business line, cash flow, and balance sheet data). It is clearly an interim financial report for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR). Q3 2016
2016-10-27 English
Milan Zdravkovic joins Sobi as Senior Vice President, Head of Research & Development
Board/Management Information Classification · 98% confidence The document announces a specific personnel change: the appointment of Milan Zdravkovic as Senior Vice President, Head of Research & Development. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is a press release format, not a comprehensive financial report (like 10-K or IR) or a regulatory filing fallback (RNS). Therefore, the appropriate code is MANG.
2016-09-26 English
Milan Zdravkovic blir Senior Vice President, Head of Research & Development på Sobi
Board/Management Information Classification · 99% confidence The document is a press release (PRESSMEDDELANDE) announcing a significant change in senior management: Milan Zdravkovic is appointed as Senior Vice President, Head of Research & Development. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2016-09-26 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.